Similarly, immunoprecipitation of ceramides in the COVID-19 plasma lipids with a commercially available monoclonal anti-ceramide IgM markedly decreased the barrier-disrupting effects of COVID-19 plasma lipids (Figure 5, C and D). The gene discussed is CD40LG; the disease is COVID-19.